Human parathyroid hormone modifications, preparation and use
    2.
    发明申请
    Human parathyroid hormone modifications, preparation and use 失效
    人甲状旁腺激素修饰,制备和使用

    公开(公告)号:US20050203012A1

    公开(公告)日:2005-09-15

    申请号:US10959605

    申请日:2004-10-07

    CPC分类号: C07K14/635 A61K38/00

    摘要: Synthetic and/or recombinant biologically active peptide derivatives of PTH(1-28), comprising a biologically active peptide at least 90% identical to a peptide consisting essentially of the formula: (a)X01ValSerGluIleGlnLeuMetHisAsn(SEQ ID NO:1); LeuGlyLysHisLeuAsnSerMetX02Arg ValGluTrpLeuArgLysLysLeu (b) fragments thereof containing amino acids 1-24, 1-25, 1-26, or 1-27; (c) pharmaceutically acceptable salts thereof; or (d) N- or C-derivatives thereof; wherein: X01 is Ser, Ala or Gly; and X02 is Glu or Arg, provided that said peptide is not hPTH(1-26)NH2, hPTH(1-27)NH2 or hPTH(1-28)NH2.

    摘要翻译: PTH(1-28)的合成和/或重组生物活性肽衍生物,其包含与基本上由下式构成的肽至少90%相同的生物活性肽:

    < colspec colname =“1”colwidth =“14PT”align =“left”/> (a) X ValSerGluIleGlnLeuMetHisAsn (SEQ ID NO:1); LeuGlyLysHisLeuAsnSerMetX Arg ROW> ValGluTrpLeuArgLysLysLeu (b)其含有氨基酸1-24,1 -25,1-26或1-27; (c)其药学上可接受的盐; 或(d)其N-或C-衍生物; 其中:X 0,1是Ser,Ala或Gly; 如果所述肽不是hPTH(1-26)NH 2,hPTH(1-27)NH 2,则X O 2是Glu或Arg, 或HPTH(1-28)NH 2。

      Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
      3.
      发明申请
      Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) 失效
      甲状旁腺激素(PTH)和甲状旁腺激素相关肽(PTHrP)的生物活性肽和肽衍生物

      公开(公告)号:US20070111946A1

      公开(公告)日:2007-05-17

      申请号:US11598011

      申请日:2006-11-13

      IPC分类号: A61K38/10 C07K7/08

      CPC分类号: C07K7/08 A61K38/00 C07K14/635

      摘要: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.

      摘要翻译: 公开了具有生物活性的新型甲状旁腺激素肽(PTH)和甲状旁腺激素相关肽(PTHrP)或其衍生物,以及含有这些肽的药物组合物,以及用于生产这些肽的合成和重组方法。 还公开了用于治疗哺乳动物病症的方法,其特征在于使用含有这种肽的治疗有效的药物组合物降低骨量。 还公开了用于筛选本发明的候选化合物对甲状旁腺激素受体作用的拮抗作用或激动作用的方法。 还公开了这些化合物的诊断和治疗方法。

      PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
      4.
      发明申请
      PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules 失效
      PTH功能结构域结合肽,其衍生物和新的束缚配体受体分子

      公开(公告)号:US20060199765A1

      公开(公告)日:2006-09-07

      申请号:US11366391

      申请日:2006-03-03

      IPC分类号: C07K14/635

      CPC分类号: C07K14/635 A61K38/00

      摘要: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.

      摘要翻译: 公开了PTH(1-34)片段的新型甲状旁腺激素(PTH)肽及其类似物,其通过以下方式组合N末端信号结构域(残基1-9)和C-末端结合结构域(残基15-31) 接头。 用于PTH(1-9) - (Gly)5-PTH(15-31)(PG5)和PTH(1-9) - (Gly)7-PTH(15-31)的核酸分子和肽和新型PTH 受体。 此外,公开了筛选PTH激动剂,药物组合物和治疗方法的方法。

      Conformationally constrained parathyroid hormone (pth) analogs
      6.
      发明申请
      Conformationally constrained parathyroid hormone (pth) analogs 有权
      构象约束甲状旁腺激素(pth)类似物

      公开(公告)号:US20050026839A1

      公开(公告)日:2005-02-03

      申请号:US10484080

      申请日:2002-07-19

      申请人: Thomas Gardella

      发明人: Thomas Gardella

      CPC分类号: C07K14/635 A61K38/00

      摘要: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH (1-34), PTH(1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11) and PTH(1-1 0) polypeptides, wherein at least one residue in each polypeptide is a helix, preferably an a-helix, stabilizing residue. The invention also provides methods of making such peptides. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.

      摘要翻译: 本发明涉及构象约束的甲状旁腺激素(PTH)类似物,以及制备和使用PTH类似物的方法。 本发明提供了在多肽的选定位置含有氨基酸取代的新型PTH多肽衍生物。 本发明提供了PTH(1-34),PTH(1-21),PTH(1-20),PTH(1-19),PTH(1-18),PTH(1-17),PTH -16),PTH(1-15),PTH(1-14),PTH(1-13),PTH(1-12),PTH(1-11)和PTH(1-10)多肽,其中 每个多肽中的至少一个残基是螺旋,优选α-螺旋的稳定残基。 本发明还提供了制备这些肽的方法。 此外,本发明包括用于限制在具有这种骨丢失风险的脊椎动物中不期望的骨丢失的组合物和方法,在治疗以不期望的骨丢失为特征的病症中,或通过对骨生长的需要。 在治疗骨折或软骨障碍并提高认为必要的细胞中的cAMP水平。

      PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
      7.
      发明申请
      PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules 审中-公开
      PTH功能结构域结合肽,其衍生物和新的束缚配体受体分子

      公开(公告)号:US20080058505A1

      公开(公告)日:2008-03-06

      申请号:US11812346

      申请日:2007-06-18

      IPC分类号: C07K14/635

      CPC分类号: C07K14/635 A61K38/00

      摘要: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1-34) fragment are disclosed that combine the N-terminal signaling domain (residues 1-9) and the C-terminal binding domain (residues 15-31) via a linker. Nucleic acid molecules and peptides for PTH(1-9)-(Gly)5-PTH(15-31) (PG5) and PTH(1-9)-(Gly)7-PTH(15-31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.

      摘要翻译: 公开了PTH(1-34)片段的新型甲状旁腺激素(PTH)肽及其类似物,其通过以下方式组合N末端信号结构域(残基1-9)和C-末端结合结构域(残基15-31) 接头。 用于PTH(1-9) - (Gly)5-PTH(15-31)(PG5)和PTH(1-9) - (Gly)7-PTH(15-31)的核酸分子和肽和新型PTH 受体。 此外,公开了筛选PTH激动剂,药物组合物和治疗方法的方法。

      Conformationally constrained parathyroid hormones with alpha-helix stabilizers
      8.
      发明申请
      Conformationally constrained parathyroid hormones with alpha-helix stabilizers 有权
      构象受限的甲状旁腺激素与α-螺旋稳定剂

      公开(公告)号:US20070161569A1

      公开(公告)日:2007-07-12

      申请号:US10549592

      申请日:2003-03-19

      申请人: Thomas Gardella

      发明人: Thomas Gardella

      IPC分类号: A61K38/10 C07K7/08

      CPC分类号: C07K14/635 A61K38/29

      摘要: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs. The invention also provides methods of preparing and using the PTH analogs. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising camp levels in cells where deemed necessary.

      摘要翻译: 本发明涉及构象约束的甲状旁腺激素(PTH)类似物和那些类似物的衍生物。 本发明还提供了制备和使用PTH类似物的方法。 此外,本发明包括用于限制在具有这种骨丢失风险的脊椎动物中不期望的骨丢失的组合物和方法,在治疗以不期望的骨丢失为特征的病症中,或通过对骨生长的需要。 在治疗骨折或软骨疾病和提高在必要的细胞中的营地水平。

      Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
      9.
      发明申请
      Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges 有权
      构象约束甲状旁腺素(pth)类似物与内酰胺桥

      公开(公告)号:US20060229240A1

      公开(公告)日:2006-10-12

      申请号:US10542704

      申请日:2003-01-24

      IPC分类号: A61K38/16 A61K38/10

      CPC分类号: C07K14/635 A61K38/29

      摘要: The present invention relates to methods of treatment of mammalian conditions characterized by decreases in bone mass with conformationally constrained parathyroid hormone (PTH) analogs and derivatives of those analogs containing PTH polypeptide derivatives containing at least one Glu or Lys substitution at position 6 and/or 10, some with installed lactam bridges between the side chains of Lys and Glu. The invention provides derivatives of PTH (1-34), PTH(1-33), PTH(1-32), PTH(1-31), PTH(1-30), PTH(1-29), PTH(1-28), PTH(1-27), PTH(1-26), PTH(1-25), PTH(1-24), PTH(1-23), PTH(1-22), PTH (1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11), PTH(1-10) and PTH(1-9) polypeptide. The invention also provides methods of preparing the PTH analogs. Further, the invention encompasses treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.

      摘要翻译: 本发明涉及治疗哺乳动物病症的方法,其特征在于具有构象约束的甲状旁腺激素(PTH)类似物的骨量减少和含有在第6位和/或第10位含有至少一个Glu或Lys取代的PTH多肽衍生物的那些类似物的衍生物 ,一些在Lys和Glu的侧链之间安装了内酰胺桥。 本发明提供了PTH(1-34),PTH(1-33),PTH(1-32),PTH(1-31),PTH(1-30),PTH(1-29),PTH -2TH),PTH(1-27),PTH(1-26),PTH(1-25),PTH(1-24),PTH(1-23),PTH(1-22) 21),PTH(1-20),PTH(1-19),PTH(1-18),PTH(1-17),PTH(1-16),PTH(1-15),PTH ),PTH(1-13),PTH(1-12),PTH(1-11),PTH(1-10)和PTH(1-9)多肽。 本发明还提供了制备PTH类似物的方法。 此外,本发明包括以不良骨丢失或骨生长需要为特征的治疗条件,例如。 在治疗骨折或软骨障碍并提高认为必要的细胞中的cAMP水平。

      Conformationally Constrained Parthyroid Hormone (Pth) Analogs
      10.
      发明申请
      Conformationally Constrained Parthyroid Hormone (Pth) Analogs 有权
      构象约束的甲状腺激素(Pth)类似物

      公开(公告)号:US20070203071A1

      公开(公告)日:2007-08-30

      申请号:US10564744

      申请日:2004-07-16

      申请人: Thomas Gardella

      发明人: Thomas Gardella

      IPC分类号: A61K38/10 C07K7/08

      CPC分类号: C07K14/635 A61K38/00

      摘要: The invention provides novel P1R polypeptide antagonists. These antagonists contain amino acid substitutions at selected positions in truncated PTH and PRHrP polypeptides and function by binding selectively to the juxtamembrane (“J”) domain of the receptor. The J domain is the region of the receptor that spans the seven transmembrane domain and the extracellular loops.

      摘要翻译: 本发明提供了新的P 1 R多肽拮抗剂。 这些拮抗剂在截短的PTH和PRHrP多肽中的选定位置含有氨基酸取代,并且通过选择性地结合受体的近红外(“J”)结构域起作用。 J结构域是跨越七个跨膜结构域和细胞外环的受体区域。